Sofinnova Ventures
Latest statistics and disclosures from Sofinnova Investments's latest quarterly 13F-HR filing:
- Top 5 stock holdings are NTRA, JAZZ, AstraZeneca, VERA, BMY, and represent 38.44% of Sofinnova Investments's stock portfolio.
- Added to shares of these 10 stocks: BMY (+$82M), AstraZeneca (+$74M), LLY (+$66M), JAZZ (+$63M), BMRN (+$41M), ABBV (+$38M), CDTX (+$28M), CNTA (+$28M), ALC (+$26M), IMNM (+$25M).
- Started 11 new stock positions in AMLX, LLY, EVMN, BMRN, RARE, MIRM, MASI, ALC, XENE, BMY. CNTA.
- Reduced shares in these 10 stocks: GILD (-$139M), AXSM (-$70M), UTHR (-$63M), BSX (-$56M), ROIV (-$52M), IBB (-$47M), , EXAS (-$27M), DXCM (-$27M), AKRO (-$23M).
- Sold out of its positions in AKRO, BSX, GILD, IBB, LQDA, PTCT, XBI, SRRK, SMMT, MRUS.
- Sofinnova Investments was a net seller of stock by $-63M.
- Sofinnova Investments has $2.3B in assets under management (AUM), dropping by 26.82%.
- Central Index Key (CIK): 0001631134
Tip: Access up to 7 years of quarterly data
Positions held by Sofinnova Ventures consolidated in one spreadsheet with up to 7 years of data
Download as csv
Download as Excel
Portfolio Holdings for Sofinnova Investments
Sofinnova Investments holds 60 positions in its portfolio as reported in the December 2025 quarterly 13F filing
| Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price | |
|---|---|---|---|---|---|---|
| Natera (NTRA) | 15.3 | $355M | 1.6M | 229.09 |
|
|
| Jazz Pharmaceuticals Shs Usd (JAZZ) | 7.0 | $163M | +63% | 960k | 170.00 |
|
| Astrazeneca Sponsored Adr | 6.5 | $150M | +98% | 1.6M | 91.93 |
|
| Vera Therapeutics Cl A (VERA) | 6.1 | $142M | 2.8M | 50.64 |
|
|
| Bristol Myers Squibb (BMY) | 3.5 | $82M | NEW | 1.5M | 53.94 |
|
| United Therapeutics Corporation (UTHR) | 3.3 | $77M | -45% | 158k | 487.25 |
|
| Vertex Pharmaceuticals Incorporated (VRTX) | 3.2 | $75M | +39% | 165k | 453.36 |
|
| Abbvie (ABBV) | 3.1 | $73M | +110% | 318k | 228.49 |
|
| Intuitive Surgical (ISRG) | 3.1 | $72M | +14% | 127k | 566.36 |
|
| Cogent Biosciences (COGT) | 3.0 | $70M | -7% | 2.0M | 35.52 |
|
| Eli Lilly & Co. (LLY) | 2.9 | $66M | NEW | 62k | 1074.68 |
|
| Rapport Therapeutics (RAPP) | 2.5 | $58M | -2% | 1.9M | 30.34 |
|
| Bridgebio Pharma (BBIO) | 2.4 | $55M | -13% | 720k | 76.49 |
|
| Avidity Biosciences Ord (RNA) | 2.3 | $54M | -14% | 745k | 72.13 |
|
| Dyne Therapeutics (DYN) | 1.9 | $44M | +128% | 2.3M | 19.56 |
|
| BioMarin Pharmaceutical (BMRN) | 1.8 | $41M | NEW | 697k | 59.43 |
|
| Apogee Therapeutics (APGE) | 1.7 | $40M | -5% | 535k | 75.48 |
|
| Cidara Therapeutics (CDTX) | 1.7 | $40M | +232% | 180k | 220.89 |
|
| Praxis Precision Medicines I (PRAX) | 1.6 | $37M | -27% | 126k | 294.74 |
|
| Immatics SHS (IMTX) | 1.6 | $36M | +54% | 3.4M | 10.50 |
|
| Inhibrx Biosciences (INBX) | 1.5 | $36M | +3% | 455k | 79.00 |
|
| Immunome (IMNM) | 1.5 | $35M | +271% | 1.6M | 21.48 |
|
| Arrivent Biopharma (AVBP) | 1.5 | $34M | 1.7M | 20.12 |
|
|
| Glaukos (GKOS) | 1.4 | $33M | -7% | 288k | 112.91 |
|
| Ideaya Biosciences (IDYA) | 1.3 | $31M | -4% | 885k | 34.57 |
|
| Bioage Labs (BIOA) | 1.3 | $30M | 2.3M | 13.23 |
|
|
| Celcuity (CELC) | 1.3 | $30M | +18% | 299k | 99.74 |
|
| Rhythm Pharmaceuticals (RYTM) | 1.3 | $29M | +9% | 271k | 107.04 |
|
| Centessa Pharmaceuticals Sponsored Ads (CNTA) | 1.2 | $28M | NEW | 1.1M | 25.01 |
|
| Supernus Pharmaceuticals (SUPN) | 1.2 | $28M | +46% | 553k | 49.70 |
|
| Insmed Com Par $.01 (INSM) | 1.2 | $27M | +50% | 157k | 174.04 |
|
| Alcon Ord Shs (ALC) | 1.1 | $26M | NEW | 333k | 78.81 |
|
| Arcus Biosciences Incorporated (RCUS) | 1.1 | $26M | -10% | 1.1M | 23.83 |
|
| Dex (DXCM) | 1.1 | $25M | -51% | 378k | 66.37 |
|
| Pharvaris N V (PHVS) | 0.9 | $21M | 745k | 27.75 |
|
|
| Nektar Therapeutics (NKTR) | 0.8 | $19M | +270% | 439k | 42.28 |
|
| Compass Therapeutics (CMPX) | 0.8 | $18M | +65% | 3.4M | 5.37 |
|
| Roivant Sciences SHS (ROIV) | 0.7 | $16M | -76% | 735k | 21.70 |
|
| Anaptysbio Inc Common (ANAB) | 0.6 | $14M | +13% | 288k | 48.48 |
|
| Ge Healthcare Technologies I Common Stock (GEHC) | 0.6 | $13M | +6% | 161k | 82.02 |
|
| Edgewise Therapeutics (EWTX) | 0.5 | $11M | -15% | 438k | 24.82 |
|
| EXACT Sciences Corporation (EXAS) | 0.4 | $10M | -72% | 101k | 101.56 |
|
| Disc Medicine (IRON) | 0.4 | $8.8M | +719% | 111k | 79.41 |
|
| Amylyx Pharmaceuticals (AMLX) | 0.3 | $6.4M | NEW | 527k | 12.08 |
|
| Masimo Corporation (MASI) | 0.3 | $6.0M | NEW | 46k | 130.06 |
|
| Uniqure Nv SHS (QURE) | 0.2 | $4.2M | -81% | 177k | 23.93 |
|
| Nextcure (NXTC) | 0.1 | $3.2M | 223k | 14.19 |
|
|
| Wave Life Sciences SHS (WVE) | 0.1 | $2.7M | -7% | 158k | 17.00 |
|
| Xenon Pharmaceuticals (XENE) | 0.1 | $2.7M | NEW | 60k | 44.82 |
|
| Evommune Com Shs (EVMN) | 0.1 | $2.6M | NEW | 153k | 17.12 |
|
| Axsome Therapeutics (AXSM) | 0.1 | $2.2M | -96% | 12k | 182.64 |
|
| Establishment Labs Holdings Ord (ESTA) | 0.1 | $2.1M | +162% | 28k | 72.88 |
|
| Ultragenyx Pharmaceutical (RARE) | 0.1 | $1.9M | NEW | 83k | 23.00 |
|
| Savara (SVRA) | 0.1 | $1.8M | -87% | 305k | 6.03 |
|
| Mirum Pharmaceuticals (MIRM) | 0.1 | $1.8M | NEW | 23k | 78.99 |
|
| ACADIA Pharmaceuticals (ACAD) | 0.1 | $1.8M | +144% | 66k | 26.71 |
|
| Jade Biosciences (JBIO) | 0.1 | $1.7M | 107k | 15.43 |
|
|
| Bolt Biotherapeutics (BOLT) | 0.0 | $753k | 138k | 5.47 |
|
|
| Soleno Therapeutics (SLNO) | 0.0 | $575k | -92% | 12k | 46.30 |
|
| Imagenebio (IMA) | 0.0 | $220k | 32k | 6.90 |
|
Past Filings by Sofinnova Investments
SEC 13F filings are viewable for Sofinnova Investments going back to 2018
- Sofinnova Investments 2025 Q4 filed Feb. 13, 2026
- Sofinnova Investments 2025 Q3 filed Nov. 14, 2025
- Sofinnova Investments 2025 Q2 filed Aug. 14, 2025
- Sofinnova Investments 2025 Q1 filed May 15, 2025
- Sofinnova Investments 2024 Q4 filed Feb. 14, 2025
- Sofinnova Investments 2024 Q3 filed Nov. 13, 2024
- Sofinnova Investments 2023 Q4 restated filed Aug. 15, 2024
- Sofinnova Investments 2024 Q1 restated filed Aug. 14, 2024
- Sofinnova Investments 2024 Q2 filed Aug. 9, 2024
- Sofinnova Investments 2024 Q1 filed May 15, 2024
- Sofinnova Investments 2023 Q3 filed Nov. 14, 2023
- Sofinnova Investments 2023 Q2 filed Aug. 14, 2023
- Sofinnova Investments 2023 Q1 filed May 11, 2023
- Sofinnova Investments 2022 Q4 filed Feb. 14, 2023
- Sofinnova Investments 2022 Q3 filed Nov. 8, 2022
- Sofinnova Investments 2022 Q2 filed Aug. 15, 2022